Fosamax (alendronate) to be promoted to PREVENT osteoporosis in postmenopausal women

    The FDA will soon allow Fosamax (alendronate) to be promoted to prevent osteoporosis in postmenopausal women.

    So far it's approved only for treatment.

    Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote